Development of A MERS-CoV Replicon Cell Line for Antiviral Screening

Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease with a high mortality of ~ 35%. The lack of approved treatments for MERS-CoV infection underscores the need for a user-friendly system for rapid drug screening. In this study, we constructe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jing, Hu, Bing-Jie, Zhao, Kai, Luo, Yun, Lin, Hao-Feng, Shi, Zheng-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898024/
https://www.ncbi.nlm.nih.gov/pubmed/33616893
http://dx.doi.org/10.1007/s12250-020-00341-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898024/
https://www.ncbi.nlm.nih.gov/pubmed/33616893
http://dx.doi.org/10.1007/s12250-020-00341-z

Ejemplares similares